Xeris Biopharma (XERS)

Executive Summary

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company specializing in ready-to-use injectable and infusible drug formulations. Leveraging its proprietary formulation technology platforms, the company addresses solubility and stability challenges to create patient-friendly delivery options. Xeris has established a commercial portfolio of three approved products targeting endocrinology, neurology, and cardiology, including Gvoke for severe hypoglycemia and Keveyis for primary periodic paralysis. The company's platform technology has potential to expand into additional therapeutic areas through partnerships and pipeline development. With a market capitalization of approximately $1.1 billion, Xeris is positioned for growth driven by commercial execution and future product launches. Looking ahead, Xeris is focusing on expanding its pipeline and advancing new product candidates. The company is developing a ready-to-use formulation of a known drug for a cardiovascular indication and is exploring partnerships for its formulation technology. Key near-term catalysts include potential FDA approval of a new drug application, initiation of a pivotal trial for a pipeline candidate, and updates on commercial performance of existing products. These events could significantly impact the company's valuation and growth trajectory.

Upcoming Catalysts (preview)

• Q1 2026Potential FDA Approval of Next-Generation Glucagon Auto-Injector75% success
• Q2 2026Initiation of Phase 3 Trial for Ready-to-Use Epinephrine Product60% success
• Q1 2026Commercial Update and Revenue Guidance for FY202690% success